Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies

PLoS Medicine

Volumn 5, Issue 12, 2008, Pages 1749-1760

  Köbel, Martin ^a,b   Kalloger, Steve E ^a   Boyd, Niki ^a   McKinney, Steven ^a   Mehl, Erika ^a   Palmer, Chana ^c   Leung, Samuel ^a   Bowen, Nathan J ^d   Ionescu, Diana N ^a   Rajput, Ashish ^a   Prentice, Leah M ^a   Miller, Dianne ^e   Santos, Jennifer ^a   Swenerton, Kenneth ^a   Gilks, C Blake ^a   Huntsman, David ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Canary Foundation   (United States)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; CANCER ANTIGEN 125; CELL SURFACE PROTEIN; CELLULAR RETINOIC ACID BINDING PROTEIN II; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; F SPONDIN; HUMAN EPIDIDYMIS PROTEIN 4; K CADHERIN; KI 67 ANTIGEN; KISSPEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRILYSIN; MATRIPTASE; MESOTHELIN; P21 ACTIVATED KINASE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P53; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SOMATOMEDIN B; TRANSCRIPTION FACTOR PAX8; TUMOR ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; UNCLASSIFIED DRUG; WILMS TUMOR SUPPRESSOR 1; TUMOR MARKER;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RISK; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; CANCER STAGING; CARCINOMA; CLASSIFICATION; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; OVARY DISEASE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

CARCINOMA; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN DISEASES; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149489177     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050232     Document Type: Article

References (41)

1. Narod SA, Boyd J (2002) Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 14: 19-26.
2. Shih I, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based oil morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518.
3. Schwartz DR, Kardia SL. Shedden KA, Kuick R, Michailidis G, et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729.
4. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, et al. (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11: 6422-6430.
5. Gilks CB, Ionescu D, Kalloger SE, Kobel M, Irving J, et al. (2008) Tumor cell type can reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39: 1239-1251.
6. Gilks CB (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23: 200-205.
7. Takano M, Kikuchi Y, Yaegashi K, Kuzuya K, Ueki M, et al. (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94: 1369-1374.
8. du Bois, Luck HJ, Meier W. Adams HP, Mobus V, et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329.
9. Fountain J, Trimble K, Birrer MJ (2006) Summary and discussion of session recommendations. Gynecol Oncol 103: S23-S25.
10. Tavasolli FA, Devilee P (2003) World Health Organization classification of tumours. Tumours of the breast and the female genital organs. Lyon (France): IARCPress-WHO.
11. Malpica A, Heavers MT, Lu K, Bodurka DC, Atkinson EN, et al. (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28: 496-504.
12. Swenerton KD (1992) Prognostic indices in ovarian cancer. Their significance in treatment planning. Acta Obstet Gynecol Scand Suppl 155: 67-74: 67-74.
13. Swenerton KD (2008) Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency. Available: http://www.bccancer.be.ca/PPI/TypesofCancer/ Ovary/default.htm. Accessed 1 April 2000
14. Singer G, Stohr R, Cope L, Dehari R, Hartmann A. et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218-224.
15. Moreno CS, Matyunina L, Dickerson EB, Schubert N, Bowen NJ, et al. (2007) Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS OXE 2: e441. doi: 10.1371/journal.pone. 0000441
16. Geisler HE, Geisler JP, Miller GA, Geisler MJ, Wiemann MC, et al. (2001) p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer 92: 781-786.
17. Viale G, Maisormeuve P, Bonoldi F, Di Bacco A. Bevilacqua P, et al. (1997) The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. Ann Oncol 8: 469-476.
18. Lee P. Rosen DG, Zhu C, Silva EG, Liu J (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96: 671-677.
19. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, et al. (2007) Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study. Gynecol Oncol 106: 318-324.
20. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, et al. (2008) Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE 3: e2633. doi:10.1371/journal.pone.0002633
21. Prentice LM, Klausen C, Kalloger S, Kobel M, McKinney S, et al. (2007) Kisspeptin and GPR54 immunoreactivity In a cohort of 518 patients defines favourable prognosis arid clear cell subtype in ovarian carcinoma. BMC Med 5: 33.
22. Lassus H, Leminen A. Lundin J, Lehtovirta P, Butzow R (2003) Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91: 504-512.
23. Turbin DA, Leung S (2008) GPEC plugin for Image J an image analyzing software. Available: http://www.gpec.ubc.ca/index.php?content=software/imagej- plugin/index.php. Accessed 20 April 2008
24. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, et al. (2007) Exquisite sensitivity of TP53 mutant, and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4; e90. doi:10. 1371/journal.pmed.0040090
25. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, et al. (2003) A gene express ion-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Nail Acad Sci U S 100: 9991-9996.
26. Lu KH, Patterson AP, Wang L, Marque/ RT, Atkinson EN, et al. (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis, din Cancer Res 10: 3291-3300.
27. Zurawski VR Jr., Orjaseter H, Andersen A, Jellum E (1988) Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 42: 677-680.
28. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, et al. (2005) Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23: 7919-7926.
29. Sillanpaa SM. Anttila MA, Voutilainen KA, Ropponen KM, Sironen RK, et al. (2006) Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int J Cancer 119: 1792-1799.
30. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S (2000) Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 19: 158-163.
31. Munstedt K, von Georgi R, Franke FE (2004) Correlation between MIB1-determined tumor growth fraction and incidence of tumor recurrence in early ovarian carcinomas. Cancer Invest 22: 185-194.
32. Khouja MH, Baekelandt M, Nesland JM, Holm R (2007) The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 26: 418-425.
33. Korkolopoulou P, Vassilopoulos I, Konstantinidou AE, Zorzos H, Patsouris E, et al, (2002) The combined evaluation of p27Kipl and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 85: 404-414.
34. Green JA, Bern's EM, Coens C, van Luijk I, Thompson-Hehir J, et al. (2006) Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur J Cancer 42: 2539-2548.
35. Anttila M, Kosma VM, Ji H, Wei-Ling X, Puolakka J, et al. (1998) Clinical significance of alpha-catenin. collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol 16: 2591-2600.
36. Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K, Kita T, et al. (2007) Clear cell adenocarcinoma associated with dear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol 31: 999-1006.
37. McShane LM, Altman DG, Sauerbrei W, Tanbe SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
38. Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, et al. (2008) Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 14: 89-96.
39. Perrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, el al. (2008) Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients. Br J Cancer 98: 1910-1915.
40. Duncan TJ, Al Attar A, Rolland P, Scott IV, Deen S, et al. (2008) Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14; 3030-3035.
41. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, et al. (2008) HOXAII DNA methylation-a novel prognostic biomarker in ovarian cancer. Int. J Cancer 123: 725-729.